PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation

被引：74
|
作者：
Ji, Mei [1 ]
Liu, Yan [2 ]
Li, Qing [3 ]
Li, Xiao-Dong [1 ]
Zhao, Wei-Qing [1 ]
Zhang, Hanze [4 ]
Zhang, Xiaofei [5 ]
Jiang, Jing-Ting [6 ]
Wu, Chang-Ping [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 3, Dept Oncol, Changzhou, Peoples R China
[2] Soochow Univ, Affiliated Hosp 3, Dept Hematol, Changzhou, Peoples R China
[3] Soochow Univ, Affiliated Hosp 3, Dept Pathol, Changzhou, Peoples R China
[4] Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL 33612 USA
[5] Tohoku Univ, Dept Clin Oncol, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan
[6] Soochow Univ, Affiliated Hosp 3, Dept Biol Treatment, Changzhou, Peoples R China
来源：
JOURNAL OF TRANSLATIONAL MEDICINE | 2015年 / 13卷
基金：
中国国家自然科学基金;
关键词：
PD-1; PD-L1; Non-small-cell lung cancer; EGFR; Gene mutation; RECEPTOR TYROSINE KINASE; CD8(+) T-LYMPHOCYTES; B7-H1; EXPRESSION; IMMUNE ESCAPE; B7; FAMILY; LIGAND; PD-1; IMMUNOTHERAPY; CARCINOMA; ANTI-PD-1;
D O I：
10.1186/s12967-014-0373-0
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Immunotherapy has become a crucial modality for non-small-cell lung cancer treatment. Recently, two immune checkpoints, PD-1 and PD-L1, have emerged as important targets for immunotherapy. Their antitumor efficacy has been confirmed by in vitro and in vivo studies. But the correlation between PD-1/PD-L1 expression and EGFR expression was controversial and needs more evidences to support the combination of PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors.
引用
收藏
页数：6
相关论文
共 50 条
  • [1] PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
    Mei Ji
    Yan Liu
    Qing Li
    Xiao-Dong Li
    Wei-Qing Zhao
    Hanze Zhang
    Xiaofei Zhang
    Jing-Ting Jiang
    Chang-Ping Wu
    Journal of Translational Medicine, 13
  • [2] PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations
    Ji, Mei
    Liu, Yan
    Li, Qing
    Li, Xiaodong
    Ning, Zhonghua
    Zhao, Weiqing
    Shi, Hongbing
    Jiang, Jingting
    Wu, Changping
    CANCER BIOLOGY & THERAPY, 2016, 17 (04) : 407 - 413
  • [3] PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
    Jing, Wang
    Li, Miaomiao
    Zhang, Yan
    Teng, Feifei
    Han, Anqin
    Kong, Li
    Zhu, Hui
    ONCOTARGETS AND THERAPY, 2016, 9 : 489 - 502
  • [4] Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer
    Meyers, D. E.
    Bryan, P. M.
    Banerji, S.
    Morris, D. G.
    CURRENT ONCOLOGY, 2018, 25 (04) : E324 - E334
  • [5] Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
    Santarpia, Mariacarmela
    Aguilar, Andres
    Chaib, Imane
    Cardona, Andres Felipe
    Fancelli, Sara
    Laguia, Fernando
    Bracht, Jillian Wilhelmina Paulina
    Cao, Peng
    Molina-Vila, Miguel Angel
    Karachaliou, Niki
    Rosell, Rafael
    CANCERS, 2020, 12 (06)
  • [6] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    D'Incecco, A.
    Andreozzi, M.
    Ludovini, V.
    Rossi, E.
    Capodanno, A.
    Landi, L.
    Tibaldi, C.
    Minuti, G.
    Salvini, J.
    Coppi, E.
    Chella, A.
    Fontanini, G.
    Filice, M. E.
    Tornillo, L.
    Incensati, R. M.
    Sani, S.
    Crino, L.
    Terracciano, L.
    Cappuzzo, F.
    BRITISH JOURNAL OF CANCER, 2015, 112 (01) : 95 - 102
  • [7] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    A D'Incecco
    M Andreozzi
    V Ludovini
    E Rossi
    A Capodanno
    L Landi
    C Tibaldi
    G Minuti
    J Salvini
    E Coppi
    A Chella
    G Fontanini
    M E Filice
    L Tornillo
    R M Incensati
    S Sani
    L Crinò
    L Terracciano
    F Cappuzzo
    British Journal of Cancer, 2015, 112 : 95 - 102
  • [8] EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis
    Yang, Huimin
    Zhu, Jinxiu
    Xiao, Rendong
    Liu, Yuhang
    Yu, Fanglin
    Cai, Lin
    Qiu, Minglian
    He, Fei
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (05) : 1001 - 1016
  • [9] EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis
    Huimin Yang
    Jinxiu Zhu
    Rendong Xiao
    Yuhang Liu
    Fanglin Yu
    Lin Cai
    Minglian Qiu
    Fei He
    Cancer Immunology, Immunotherapy, 2022, 71 : 1001 - 1016
  • [10] PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis
    Li, Jing
    Gu, Jian
    FUTURE ONCOLOGY, 2019, 15 (14) : 1667 - 1678
12345